Nyxoah (NYXH)
NASDAQ:NYXH
NYXH Stock Chart & Stats
$3.30
-$0.38(-3.86%)
At close: 4:00 PM EST
$3.30
-$0.38(-3.86%)
Day’s Range― - ―
52-Week Range$2.76 - $8.64
Previous CloseN/A
Volume100.61K
Average Volume (3M)38.97K
Market Cap
$130.37M
Enterprise Value$146.59M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.86
Next Earnings
May 19, 2026EPS Estimate
-0.59Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.68
Shares Outstanding43,662,403
10 Day Avg. Volume31,997
30 Day Avg. Volume38,970
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.12
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$9.98Price Target Upside202.42% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Market PotentialThe target market for Genio in the U.S. is approximately 510,000 patients, representing an annual total addressable market of approximately $10 billion.
Regulatory MilestonesThe FDA has issued an Approvable Letter for Nyxoah's Genio system, indicating a positive step towards full market approval.
Bears Say
Regulatory DelaysThere is an issue with the FDA’s acceptance of data regarding manufacturing processes, delaying the anticipated approval.
Sales Performance4Q24 Genio sales were below estimates, with reported sales of €1.3M compared to an expected €2.4M.
Nyxoah News
NYXH FAQ
What was Nyxoah’s price range in the past 12 months?
Nyxoah lowest stock price was $2.76 and its highest was $8.64 in the past 12 months.
What is Nyxoah’s market cap?
Nyxoah’s market cap is $130.37M.
When is Nyxoah’s upcoming earnings report date?
Nyxoah’s upcoming earnings report date is May 19, 2026 which is in 40 days.
How were Nyxoah’s earnings last quarter?
Nyxoah released its earnings results on Mar 19, 2026. The company reported -$0.683 earnings per share for the quarter, missing the consensus estimate of -$0.634 by -$0.049.
Is Nyxoah overvalued?
According to Wall Street analysts Nyxoah’s price is currently Undervalued.
Does Nyxoah pay dividends?
Nyxoah does not currently pay dividends.
What is Nyxoah’s EPS estimate?
Nyxoah’s EPS estimate is -0.59.
How many shares outstanding does Nyxoah have?
Nyxoah has 43,662,403 shares outstanding.
What happened to Nyxoah’s price movement after its last earnings report?
Nyxoah reported an EPS of -$0.683 in its last earnings report, missing expectations of -$0.634. Following the earnings report the stock price went down -0.324%.
Which hedge fund is a major shareholder of Nyxoah?
Currently, no hedge funds are holding shares in NYXH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nyxoah Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.98 (202.42% Upside)
$9.98 (202.42% Upside)
Blogger Sentiment
Bullish
NYXH Sentiment 100%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-57.18%
12-Months-Change
Fundamentals
Return on Equity
-116.16%
Trailing 12-Months
Asset Growth
-15.17%
Trailing 12-Months
Company Description
Nyxoah
Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. It offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
NYXH Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlights a successful regulatory milestone (FDA approval), clear early commercial traction in the U.S., rapid revenue acceleration (+122% FY 2025) and healthy gross margins (63-64%), supported by reimbursement progress and salesforce expansion. However, the company is investing heavily to commercialize—resulting in a materially larger full-year operating loss (+~42%)—and faces near-term cash burn (≈EUR 20M/quarter) with limited runway into early 2027 unless revenue ramps as guided. Reimbursement coding and lack of disclosed implant counts create some execution and transparency risks. On balance, the strong growth, product differentiation, and reimbursement wins outweigh the financial and operational risks in the near term.View all NYXH earnings summariesNYXH Stock 12 Month Forecast
Average Price Target
$9.98
▲(202.42% Upside)
Technical Analysis
Irhythm Technologies
―
Inspire Medical Systems
―
Senseonics Holdings
―
Stereotaxis
―
NovoCure
―
Smith & Nephew Snats
―
Ownership Overview
―
Insiders
0.84% Mutual Funds
5.03% Other Institutional Investors
94.13% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---